Cannabis Law Report

AUGUST 27, 2021

The Board will advise Delic and its subsidiaries, including Ketamine Infusion Centers, Delic Labs and others, as they develop safety protocols and best practices pertaining to legal psychedelic wellness treatments today and those legalized in the future. About Delic Corp, Inc.

Research and Development 98

Research and Development Treatment Media Medicine 98

The Joint Blog

APRIL 17, 2020

This study summarizes potential adverse drug events related to THC when combined with other medications Medicinal Use of Marijuana Cannabis has been used widely across North America in various state or provincial medical marijuana programs. Diminishing efficacy of these receptors over time should be considered for proper treatment.

Events 48

Events THC Chronic Pain Sleep 48

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). Some of these studies have shown positive results, but adverse events were also noted. Fletcher S.

Clinical Trials 52

Clinical Trials Events Therapy Sleep 52

Medicinal Genomics

JANUARY 10, 2024

Since then, CannMed has transformed into an industry event that attracts the brightest minds in cannabis science, medicine, cultivation, and safety testing. The event received overwhelming praise from attendees, who valued the networking, prospecting, education, and community.

Research and Development 52

Research and Development Events Education Medicine 52

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. The FDA has received adverse event reports involving delta-8 THC-containing products. brownies, gummies).

THC 105

THC Pets Events Hemp 105

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JUNE 14, 2022

Ketamine is already registered for the treatment of depression and in 2023, the FDA might approve an MDMA assisted therapy for PTSD. However, there is a growing realization that European health systems may not be prepared for these treatments. Psychedelic compounds – such as psilocybin and MDMA – are one such extremely promising area.

Access 52

Access Therapy Clinical Trials Treatment 52

Veriheal

JUNE 30, 2023

To start, participants reported that psilocybin had helped them process emotions tied to painful events in their past. Additionally, participants also reported feeling increased self-awareness and general improvement in relationships following their treatment. The Summit found that cannabis does not enhance athletic performance.

Clinical Trials 92

Clinical Trials Research and Development Therapy Policy 92

MMJ Recs

DECEMBER 20, 2023

The establishment of medical marijuana dispensaries in Virginia represents a progressive approach to healthcare, offering patients alternative treatment options for various medical conditions. Patients must obtain a written certification from a registered healthcare practitioner affirming their eligibility for medical marijuana treatment.

Dispensary 52

Dispensary Marijuana Strains Patients 52

TheAnswerPage

OCTOBER 6, 2021

months of treatment, with 60% of patients experiencing a treatment-related adverse event, 96% of which were mild or moderate. Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial. JAMA Netw Open. 2021;4(9):e2123930.

Sleep 52

Sleep Treatment Concentrates Safety 52

Cannabis Law Report

JULY 29, 2021

Tetra Bio-Pharma ( TSX: TBP ) ( OTCQB: TBPMF ) ( FRA:JAM1 ) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. For more information visit: www.tetrabiopharma.com.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

JULY 24, 2021

This expansive patent would allow Mydecine to scale its coverage in drug development research in lieu of promising discoveries and FDA-approval progress for novel therapeutics, including granting Breakthrough Therapy Designation to MDMA for the treatment of PTSD in recent years. About Mydecine Innovations Group.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

DECEMBER 3, 2021

Extended Duration Safety and Efficacy of Adjunctive Ganaxolone Treatment in Patients with CDKL5 Deficiency Disorder: 8-Month Minimum Open-Label Extension Follow-up. Safety findings from this OLE analysis are consistent with the safety in the double-blind phase as well as the known safety profile of gananxolone.

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Veriheal

MARCH 18, 2021

They needed a model for Alzheimer’s disease in order to effectively review cannabidiol (CBD) as a potential treatment. Unfortunately, both of these conditions result in cognitive decline and suffer from a lack of effective treatment. Why Aging Cats? What Did The Study Find?

CBD 82

CBD Research and Development Pets Treatment 82

CannaMD

JULY 2, 2020

To review Columbia Care’s COVID-19 delivery/pick-up and safety policies, please see: Florida Dispensaries: Coronavirus Policies. Curaleaf is offering two great sales events: Stock Up To Save Big : July 2 – July 3. On July 3, save an additional 10% in store if you wear red, white, and blue! 1/8th of Modern Flower GG4xSuper Skunk.

Safety 81

Safety Policy Marijuana Dispensary 81

Cannabis Law Report

OCTOBER 22, 2021

–The Company expects to hold a Research & Development event to review,these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media– TORONTO, CANADA – October 19, 2021 – Cybin Inc.

Research and Development 52

Research and Development Safety Media Data 52

Cannabis Law Report

JANUARY 12, 2022

As Oregon prepares to roll out the nation’s first legal psilocybin-assisted services program, there is a recognized need for the community to track adverse events and measure efficacy. We don’t believe safety and access are opposing polarities that must be constantly balanced.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

The Cannigma

OCTOBER 21, 2021

Simon is not alone, one study reviewed online forum posts about cannabis and ADHD and found that 25% of posts indicated therapeutic benefits from this treatment – with statements like “While you are high … you will be able to focus much, much better than you normally would” and “(cannabis) helps me greatly with my ADHD.”

Blood Pressure 137

Blood Pressure Treatment Patients Cannabis 137

Cannabis Law Report

MAY 27, 2022

The signing event was observed by the Royal Thai Police, the Office of the Narcotics Control Board and the Food and Drug Administration. Homegrown cannabis will help save money for some patients who need to use the plant for medical treatments,” he said. “Registration is required for household growing.

Recreational 52

Recreational Research and Development Food Extraction 52

Cannabis Law Report

JULY 14, 2021

The exploratory trial was the latest of several small trials where ImmunoFlex has focused on analysing immune system modulation at a genomic level resulting from treatment with compounds including CBD, THC, NAC and several other widely available compounds. Forward-looking statements are statements that relate to future, not past, events.

Research and Development 105

Research and Development Clinical Trials Events Treatment 105

Cannabis Law Report

OCTOBER 6, 2021

Delic Labs is leading the way in psychedelic compound testing and ensuring the safety and effectiveness of any treatments produced using them, while also actively researching potential new medicines for the market.”. About DELIC Corp. The Canadian Securities Exchange ?

Research and Development 52

Research and Development Extraction Treatment Safety 52

Cannabis Law Report

JULY 28, 2021

InnarisBio), to develop a novel sol-gel intranasal drug delivery technology to improve treatments for mental health disorders. InnarisBio aims to be a revolutionary technology company for intranasal drug delivery in the treatment of CNS disorders. A potential solution is direct nose-to-brain delivery. About atai Life Sciences.

Research and Development 98

Research and Development Programs Treatment Media 98

Cannabis Law Report

APRIL 13, 2022

Securing a Dealer’s License to accompany its existing research exemptions would cement Delic Labs’ position as the leader in psychedelic safety testing. The Company aims to establish consistent quality control standards as more patients and clinicians incorporate psychedelic compounds into treatment plans.

Research and Development 52

Research and Development Treatment Extraction Medicine 52

Puff Puff Post

MARCH 10, 2020

.” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

FloridaMarijuana.net

JULY 8, 2018

The National Academies of Sciences reports that PTSD is a stressor-related disorder which develops as a result of a patient’s exposure to a traumatic event. While there is a popular belief that Indica strains are the best treatment, a variety of genetics (Hybrid, Sativa, CBD) may alleviate the symptoms of PTSD.

Strains 190

Strains Indica Hybrid Research and Development 190

Cannabis Law Report

AUGUST 3, 2021

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law. – Phase 2 Trial Underway.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

SEPTEMBER 22, 2022

AB 1885 expands the purpose of the comprehensive system established by Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA) to include the control and regulation of the cultivation, distribution, transport, storage, manufacturing, processing, and sale of cannabis products intended for use on, or consumption by, animals.

Law 52

Law Events Packaging Pets 52

Cannabis Law Report

JUNE 23, 2021

The analysis of patient-reported outcome measures following treatment with cannabis-based medicinal products (CBMPs) in a study covering patients with all conditions found statistically significant improvements in anxiety, sleep , and general quality of life at one, three, and six months following treatment, compared to baseline assessment.

Cannabinoids 59

Cannabinoids Data Chronic Pain Sleep 59

MMJ Recs

MARCH 2, 2024

Observing discretion in discussions regarding medical conditions and treatment enhances privacy and respect among patrons. Additionally, adhering to dispensary policies on product handling and consumption promotes harmony and safety.

Dispensary 52

Dispensary Patients Marijuana Education 52

Cannabis Law Report

JULY 1, 2021

In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency identified psilocybin as a breakthrough for treatment-resistant depression. These developments indicate that psychedelics may represent substantial improvements over existing treatments for mental illness. The Project.

Law 59

Law Policy Research and Development Clinical Trials 59

Cannabis Law Report

JANUARY 20, 2022

Event Details. Working with those in treatment to those seeking accelerated personal growth, Field Trip Health believe psychedelics and psychedelic-assisted psychotherapy offer an accessible, evidence-based way to heal and heighten engagement with the world. Mon, Jan 24, 2022 at 6:30 PM. More info: [link]. Dustin Robinson, Esq.

Therapy 52

Therapy Research and Development Access Events 52

Cannabis Law Report

AUGUST 24, 2021

The Company has previously successfully completed a Phase 1 first-in-human safety and tolerability study for FSD-201 and the compound to be safe with no serious adverse side effects.

Clinical Trials 105

Clinical Trials Treatment Pharmaceutical Concentrates 105

The Joint Blog

JUNE 28, 2019

According to new research, the use of marijuana is a safe and effective treatment for those with fibromyalgia. The study, titled Safety and efficacy of medical cannabis in fibromyalgia, was published by the Journal of Clinical Medicine and was published online by the U.S. 0.72), concerns about cannabis treatment (OR 0.36, 95% C.I

Therapy 44

Therapy Chronic Pain Treatment Marijuana 44

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

MAY 18, 2022

A recent publication in the prominent peer-reviewed journal Nature, shows that 67% of patients no longer qualified for a PTSD diagnosis a year after treatment with MDMA (or “ecstasy”). Over 40 key opinion leaders from all over the world will be participating in the event.

Research and Development 52

Research and Development Therapy Treatment Policy 52